US 11,952,362 B2
Compositions and methods for treating epigenetic disease
Dimitrios Iliopoulos, Los Angeles, CA (US); Michael E. Jung, Los Angeles, CA (US); Jonghoon Kim, Los Angeles, CA (US); Jill M. Hoffman, Sherman Oaks, CA (US); and Iordanes Karagiannides, North Hollywood, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/262,081
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Jul. 22, 2019, PCT No. PCT/US2019/042746
§ 371(c)(1), (2) Date Jan. 21, 2021,
PCT Pub. No. WO2020/023333, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/702,183, filed on Jul. 23, 2018.
Prior Publication US 2021/0309634 A1, Oct. 7, 2021
Int. Cl. C07D 401/06 (2006.01); A61P 1/04 (2006.01); C07D 409/06 (2006.01)
CPC C07D 401/06 (2013.01) [A61P 1/04 (2018.01); C07D 409/06 (2013.01)] 11 Claims
 
1. A compound of formula I, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
R1 is pyrrolyl, pyridinyl, or pyrazinyl, each of which is optionally substituted with one or more groups selected from alkyl and halo; and
R2 is alkyl.